Dec 30, 2021 7:00 am EST Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
Nov 05, 2021 7:30 am EDT Immunovant Reports Financial Results for the Quarter Ended September 30, 2021
Jun 01, 2021 7:31 am EDT Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021
Feb 16, 2021 8:00 am EST Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020